Avior
Amount not stated
February 2024
Engagement of Avior to develop a novel oral itraconazole capsule formulation, including formulation development, clinical supplies and a pilot pharmacokinetic study.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Francis E. O’Donnell
Also a director
Executive Chairman of the Board and Chief Executive Officer
|
76 | Not stated | Not stated | $1,118,630 | |
|
James A. McNulty
Interim Chief Financial Officer, Treasurer and Secretary
|
75 | Not stated | Not stated | $362,574 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Engagement of Avior to develop a novel oral itraconazole capsule formulation, including formulation development, clinical supplies and a pilot pharmacokinetic study.
Loading...
